Osiris Therapeutics (OSIR) researches, develops, manufactures, markets, and distributes regenerative medicine products.
OSIR products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
November 7, 2019
RegMed Investors’ (RMi) closing bell: the sector bounced to the upside
November 6, 2019
Regenerative Medicine Earnings Scorecard - Q3/19 - to date
November 6, 2019
RegMed Investors’ (RMi) closing bell: Framing the main takeaway … pricing, volume and volatility!
November 4, 2019
RegMed Investors’ (RMi) closing bell: the market rips, the sector dips on the second session of November
October 31, 2019
RegMed Investors’ (RMi) closing bell: The sector risks are still to the downside
October 30, 2019
RegMed Investors’ (RMi) closing bell: strength came from trading the downside
October 29, 2019
RegMed Investors’ (RMi) closing bell: hard to grow, easy to go as the sector flip flops with an Advance/Decline (A/D) line downslide
35 companies, 1 interpreter!
Insight, foresight and recommendation
Osiris Therapeutics (OSIR) – Late Filing, SEC issues, officer crimminal indictments and yet another COO departs (number 5 in four years?). Started the year 2018 at $6.15, dived and jived to $6.95 by 2/1 and achieved $9.08 by 2/21. Once their "clean" it will be worth a near term topic until then "play" monopoly with the shares ... NO trust
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors